Behavioral and Cognitive Therapies for Auditory Hallucination Management

Behavioral and Cognitive Therapies for Auditory Hallucination Management: Effectiveness and Analysis of Change Processes Involved With Hallucinations in a Population Suffering From Chronic Psychosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03348787

Acronym

AcceptVoice

Enrollment

Registered

2017-11-21

Start date

2017-12-13

Completion date

2020-06-30

Last updated

2020-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Psychosis

Keywords

Behavioral and Cognitive Therapies

Brief summary

The present study wants to evaluate the efficacy of a short psychoeducational type group intervention and Cognitive behavioral therapy (CBT) 3rd wave on the severity of hallucinatory Acoustico-Verbal (HAV) symptomatology in patients with schizophrenia.

Interventions

BEHAVIORALBehavioral and Cognitive Therapies

Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Schizophrenic disorders, schizo-affective disorders * Suffering from persistent HAV * No change in symptomatology for 3 months. * No anticipated change in antipsychotic treatment (anti-hallucinatory): olanzapine, risperidone, amisulpride, quetiapine, aripiprazole, loxapine, haloperidol, clopixol, modecate, nozinan, cyamemazine, piportil, clozapine * Major patient, or major incompetent.

Exclusion criteria

* Mental retardation * Subject participating in another search including an exclusion period still in progress at pre-inclusion

Design outcomes

Primary

Measure	Time frame	Description
intensity HAV symptoms	Baseline and one week after the last session	Difference between the Psychotic Symptom Rating Scales (PSYRATS) on HAV symptom score administered before the first therapeutic group session and the PSYRATS symptom score administered 1 week after the last group session. The PSYRATS Scales measure dimensions of hallucinations and delusions.

Secondary

Measure	Time frame	Description
Effect over time	Until 12 months after the last session	Difference between the PSYRATS score given 1 week before the first session, and the PSYRATS score administered one week after the last session and then at 6 weeks, 6 months and 12 months.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026